Natalizumab (Solution)

Cat. No.: HY-108831A Purity: 98.72%: Data Sheet
SDS

COA
Technical Support

Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses.

For research use only. We do not sell to patients.

Natalizumab (Solution) Chemical Structure

CAS No. : 189261-10-7

Size	Price	Stock	Quantity
5 mg	USD 252	In-stock	Estimated Time of Arrival: April 8
10 mg	USD 410	In-stock	Estimated Time of Arrival: April 8
25 mg	USD 819	In-stock	Estimated Time of Arrival: April 8
50 mg	USD 1313	In-stock	Estimated Time of Arrival: April 8
100 mg	USD 2100	In-stock	Estimated Time of Arrival: April 8
200 mg		Get quote
500 mg		Get quote

Get it by April 8 for select sizes. Order within 20 hrs 47 mins.

or Bulk Inquiry

* Please select Quantity before adding items.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Natalizumab (Solution):

Natalizumab Get quote

2 Publications Citing Use of MCE Natalizumab (Solution)

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Integrin Isoform Specific Products:

View All Isoforms

αvβ1 αvβ3 αvβ5 αvβ6 αvβ8 α5β1 α1β1 α2β1 α4β1 α9β1 αIIbβ3 α4β7 αLβ2

Biological Activity
Purity & Documentation
References
Customer Review

Description

Isotype

Human IgG4 kappa

Recommend Isotype Controls

Human IgG4 (S228P) kappa, Isotype Control

Species

Humanized

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01943526	Biogen	Relapsing-Remitting Multiple Sclerosis	November 30, 2011
NCT00675428	Biogen	Multiple Myeloma	September 2008	Phase 1\|Phase 2
NCT01077466	Rigshospitalet, Denmark\|Copenhagen University Hospital, Hvidovre\|Biogen\|University of Copenhagen\|Signifikans ApS	Primary Progressive Multiple Sclerosis\|Secondary Progressive Multiple Sclerosis	March 2010	Phase 2
NCT01440101	Biogen	Multiple Sclerosis	November 2010	Phase 2\|Phase 3
NCT01955707	Biogen	Acute Ischemic Stroke	January 2014	Phase 2
NCT00707512	Biogen	Crohn´s Disease	June 2008
NCT05304520	Biogen	Relapsing-Remitting Multiple Sclerosis (RRMS)	October 12, 2021
NCT01884935	Biogen	Relapsing-Remitting Multiple Sclerosis	July 2013	Phase 1
NCT05265728	Biogen	Multiple Sclerosis, Relapsing-Remitting	April 26, 2022	Phase 3
NCT04964700	Multiple Sclerosis Center of Northeastern New York	Multiple Sclerosis	May 6, 2021
NCT00276172	Biogen	Multiple Sclerosis	December 2003	Phase 3
NCT05532163	Biogen	Multiple Sclerosis, Relapsing-Remitting	January 23, 2023	Phase 4
NCT00559702	Biogen\|Elan Pharmaceuticals	Relapsing-Remitting Multiple Sclerosis\|Secondary Progressive Multiple Sclerosis	October 2007	Phase 1
NCT00942214	University Hospital, Toulouse	Multiple Sclerosis	June 2009	Phase 4
NCT02342704	Biogen	Relapsing-Remitting Multiple Sclerosis	November 30, 2014	Phase 4
NCT01416181	Biogen	Secondary Progressive Multiple Sclerosis	September 13, 2011	Phase 3
NCT02677077	Biogen	Relapsing-Remitting Multiple Sclerosis	December 31, 2015
NCT03516526	Amsterdam UMC, location VUmc\|Prothya Biosolutions\|Erasmus Medical Center\|St. Antonius Hospital\|OLVG\|Rijnstate Hospital	Multiple Sclerosis	November 3, 2016	Phase 4
NCT04048577	Berkovich, Regina MD, PhD Inc.\|Biogen\|Cedars-Sinai Medical Center	Multiple Sclerosis\|Multiple Sclerosis, Relapsing-Remitting	July 3, 2019	Phase 4
NCT00032799	Biogen\|Elan Pharmaceuticals	Crohn´s Disease	December 2001	Phase 3
NCT01416155	Biogen	Relapsing-Remitting Multiple Sclerosis\|Multiple Sclerosis	October 2010	Phase 2
NCT00306592	Biogen\|Elan Pharmaceuticals	Multiple Sclerosis, Relapsing-Remitting	March 2006	Phase 3
NCT02775110	University at Buffalo	Multiple Sclerosis	November 2012	Phase 4
NCT03283371	Biogen	Epilepsy, Focal Seizures, Partial Seizures	March 20, 2018	Phase 2
NCT05618301	Washington University School of Medicine\|BioLineRx, Ltd.\|Biogen	Sickle Cell Disease	July 7, 2023	Phase 1
NCT01058005	Biogen\|Elan Pharmaceuticals	Relapsing Remitting Multiple Sclerosis	March 2010	Phase 3
NCT02176031	Dana-Farber Cancer Institute\|Biogen	Graft Versus Host Disease	January 2015	Phase 2
NCT05925049	Biogen	Multiple Sclerosis	June 30, 2023
NCT01455220	University of South Florida	Multiple Sclerosis	January 2011	Not Applicable
NCT05688436	Biogen	Multiple Sclerosis	September 24, 2021
NCT01485003	Biogen	Relapsing-Remitting Multiple Sclerosis	February 7, 2012
NCT00831649	Biogen\|Elan Pharmaceuticals	Rheumatoid Arthritis	September 2004	Phase 2
NCT01070823	Biogen\|United BioSource, LLC\|Elan Pharmaceuticals	Multiple Sclerosis	March 2010
NCT00055536	Biogen\|Elan Pharmaceuticals	Crohn´s Disease	April 2002	Phase 2
NCT03811886	Case Comprehensive Cancer Center	Pulmonary Metastatic Osteosarcoma (pOS)	October 1, 2023	Phase 1\|Phase 2
NCT02241785	Biogen	Relapsing Multiple Sclerosis	September 30, 2014	Phase 4
NCT01065727	Rennes University Hospital	Multiple Sclerosis	February 2010	Not Applicable
NCT00032786	Biogen\|Elan Pharmaceuticals	Crohn´s Disease	March 2002	Phase 3
NCT04832399	Biogen	Relapsing Remitting Multiple Sclerosis	November 12, 2013
NCT03046251	State University of New York at Buffalo	Multiple Sclerosis	August 2015	Phase 4
NCT00536120	Biogen	Multiple Sclerosis	January 2008	Phase 4
NCT01071083	Biogen\|Elan Pharmaceuticals	Relapsing Remitting Multiple Sclerosis	March 2010	Phase 2
NCT05701423	Biogen	Multiple Sclerosis	February 8, 2023
NCT00097760	Biogen\|Elan Pharmaceuticals	Multiple Sclerosis, Relapsing-Remitting	June 2003	Phase 2
NCT00871780	Biogen\|Elan Pharmaceuticals	Relapsing Remitting Multiple Sclerosis (RRMS)	August 2009	Phase 4
NCT05762003	IMPULS Endowment Fund	Multiple Sclerosis	January 1, 2019
NCT02386566	Biogen	Multiple Sclerosis	March 20, 2015
NCT04580381	University Hospital, Caen\|Biogen	Multiple Sclerosis, Relapsing-Remitting	September 1, 2020
NCT05236777	Biogen\|Association for Functional Rehabilitation, Recreation and Applied Kinesiology Impulse	Multiple Sclerosis	January 1, 2019
NCT04777539	Nantes University Hospital\|Rennes University Hospital	Multiple Sclerosis (MS)	June 14, 2021
NCT01591551	Cornerstone Health Care, PA\|Biogen	Multiple Sclerosis, Relapsing-Remitting	March 2012	Phase 4
NCT00744679	Biogen\|Elan Pharmaceuticals	Multiple Sclerosis	November 2008	Phase 4
NCT00078611	Biogen\|Elan Pharmaceuticals	Crohn´s Disease	March 2004	Phase 3
NCT03689972	Biogen	Multiple Sclerosis, Relapsing-Remitting	November 27, 2018	Phase 3
NCT04225312	Amsterdam UMC, location VUmc\|Stichting MS Research\|Innovatiefonds Zorgverzekeraars\|Stichting Treatmeds	Relapsing Remitting Multiple Sclerosis	February 3, 2020	Phase 4
NCT02137109	Biogen	Multiple Sclerosis	March 2014
NCT00027300	Biogen\|Elan Pharmaceuticals	Multiple Sclerosis, Relapsing-Remitting	November 2001	Phase 3
NCT05177718	Vanderbilt University Medical Center\|Biogen	Multiple Sclerosis	September 16, 2022	Phase 4
NCT00055367	Biogen\|Elan Pharmaceuticals	Crohn´s Disease	April 2002	Phase 2
NCT00083759	Biogen\|Elan Pharmaceuticals	Rheumatoid Arthritis	May 2004	Phase 2
NCT00280956	Biogen\|Elan Pharmaceuticals	Crohn´s Disease	July 2002	Phase 4
NCT02159573	Biogen	Relapsing-Remitting Multiple Sclerosis	July 2014
NCT03093064	King´s College London\|South London and Maudsley NHS Foundation Trust	Schizophrenia	April 1, 2017	Phase 1
NCT02769689	University Hospital, Clermont-Ferrand	Multiple Sclerosis	June 12, 2019	Phase 4
NCT02142192	Biogen	Relapsing Multiple Sclerosis	December 2014	Phase 2
NCT02730455	Biogen	Acute Ischemic Stroke	July 18, 2016	Phase 2
NCT01070836	Biogen	Relapsing Multiple Sclerosis	March 2010
NCT02483845	Phoenix Neurological Associates, LTD	Inclusion Body Myositis (IBM)	May 2013	Phase 1
NCT00884481	Biogen	Relapsing-Remitting Multiple Sclerosis\|Fatigue	March 23, 2009
NCT01144052	Claudio Gobbi\|Ospedale Civico, Lugano	Relapsing-remitting Multiple Sclerosis	June 2010	Phase 4
NCT02133924	John Levine\|Biogen\|Icahn School of Medicine at Mount Sinai	Acute Graft Versus Host Disease	August 2016	Phase 2
NCT00297232	Biogen	Relapsing-Remitting Multiple Sclerosis	March 2006	Phase 3
NCT00424788	Biogen	Relapsing Forms of Multiple Sclerosis	January 2007	Early Phase 1
NCT00801125	Biogen\|Elan Pharmaceuticals	Crohn´s Disease	December 2008	Phase 4
NCT02325440	University Hospital Muenster\|Novartis	Relapsing Remitting Multiple Sclerosis	March 2014	Phase 4
NCT00030966	Biogen\|Elan Pharmaceuticals	Multiple Sclerosis, Relapsing-Remitting	January 2002	Phase 3
NCT05627271	Novartis Pharmaceuticals\|Novartis	Multiple Sclerosis	January 10, 2023
NCT00818038	Biogen	Relapsing-Remitting Multiple Sclerosis	March 2009
NCT01405820	Biogen	Relapsing-Remitting Multiple Sclerosis	August 2011	Phase 2

CAS No.

189261-10-7

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Natalizumab (Solution)]

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Purity: 98.72%

Select Batch:

Data Sheet (256 KB) SDS (251 KB)

COA (231 KB)

Inhibitory Antibodies User Guide (602 KB)

References

[1]. Hutchinson M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007 Jun;3(2):259-68. [Content Brief]